These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 32478236)
1. Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90. Pinzi L; Benedetti R; Altucci L; Rastelli G ACS Omega; 2020 May; 5(20):11473-11480. PubMed ID: 32478236 [TBL] [Abstract][Full Text] [Related]
2. Searching for Novel HDAC6/Hsp90 Dual Inhibitors with Anti-Prostate Cancer Activity: In Silico Screening and In Vitro Evaluation. Pinzi L; Belluti S; Piccinini I; Imbriano C; Rastelli G Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204176 [TBL] [Abstract][Full Text] [Related]
3. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90). Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503 [TBL] [Abstract][Full Text] [Related]
4. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors. Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697 [TBL] [Abstract][Full Text] [Related]
5. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. Suzuki T; Kouketsu A; Itoh Y; Hisakawa S; Maeda S; Yoshida M; Nakagawa H; Miyata N J Med Chem; 2006 Aug; 49(16):4809-12. PubMed ID: 16884291 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer. Chen J; Sang Z; Jiang Y; Yang C; He L Chem Biol Drug Des; 2019 Mar; 93(3):232-241. PubMed ID: 30251407 [TBL] [Abstract][Full Text] [Related]
7. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase 6 in cancer. Li T; Zhang C; Hassan S; Liu X; Song F; Chen K; Zhang W; Yang J J Hematol Oncol; 2018 Sep; 11(1):111. PubMed ID: 30176876 [TBL] [Abstract][Full Text] [Related]
9. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Zhang Y; Kwon S; Yamaguchi T; Cubizolles F; Rousseaux S; Kneissel M; Cao C; Li N; Cheng HL; Chua K; Lombard D; Mizeracki A; Matthias G; Alt FW; Khochbin S; Matthias P Mol Cell Biol; 2008 Mar; 28(5):1688-701. PubMed ID: 18180281 [TBL] [Abstract][Full Text] [Related]
10. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies. Uba AI; Yelekçi K Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease. Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418 [TBL] [Abstract][Full Text] [Related]
12. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression. Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP Eur J Med Chem; 2020 Jan; 185():111725. PubMed ID: 31655430 [TBL] [Abstract][Full Text] [Related]
13. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs. Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307 [TBL] [Abstract][Full Text] [Related]
14. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis. Ryu HW; Shin DH; Lee DH; Choi J; Han G; Lee KY; Kwon SH Cancer Lett; 2017 Apr; 391():162-171. PubMed ID: 28153791 [TBL] [Abstract][Full Text] [Related]
15. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Kovacs JJ; Murphy PJ; Gaillard S; Zhao X; Wu JT; Nicchitta CV; Yoshida M; Toft DO; Pratt WB; Yao TP Mol Cell; 2005 May; 18(5):601-7. PubMed ID: 15916966 [TBL] [Abstract][Full Text] [Related]
16. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness. Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427 [TBL] [Abstract][Full Text] [Related]
17. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells. Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558 [TBL] [Abstract][Full Text] [Related]
18. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815 [TBL] [Abstract][Full Text] [Related]
19. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC. Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459 [TBL] [Abstract][Full Text] [Related]